Navigation Links
Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Date:7/1/2011

GAITHERSBURG, Md., July 1, 2011 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced the appointment of Dave Lemus as its new vice president of finance, effective July 1, 2011.  Lemus will join the leadership team at Sigma-Tau Pharmaceuticals U.S. corporate headquarters in Gaithersburg, Md.

For the past 13 years, Lemus served as chief financial officer of MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX), one of the Europe's leading biotechnology companies focused on fully human antibodies.  In this position, he held responsibilities for a variety of areas, including corporate development, technical operations, corporate legal, human resources, and public and investor relations.  In 1999, Lemus led the effort to take the company public, successfully completing Germany's first-ever biotech initial public offering.  For the next decade thereafter, he played a central role in helping grow the company into one of Europe's leading life science companies.

"I'm very pleased to become part of the Sigma-Tau growth story going forward as its new vice president of finance," commented Lemus.  "Moreover, Sigma-Tau's considerable expertise in rare diseases will continue to play a decisive role in propelling the company's high rate of growth and expansion over the coming years."

Prior to his role at MorphoSys AG, Lemus was a controller and operations manager at Hoffmann-La Roche, and preceding this position, he served as the treasurer of the Lindt Chocolate Company.

"As a leader in the development and commercialization of medicines for rare diseases, we have undergone tremendous growth in the past few years," said Gregg Lapointe, CEO, Sigma-Tau Pharmaceuticals, Inc.  "In looking to the future, it's imperative we have talented people like Dave to help Sigma-Tau continue to bring innovation to the field of rare diseases.  We're very pleased to welcome him to the team."

Sigma-Tau Pharmaceuticals, Inc. is dedicated to creating novel medicines for the unmet needs of patients with rare diseases.  

About Sigma-Tau Pharmaceuticals, Inc.
Sigma-Tau Pharmaceuticals, Inc. is a U.S.-based, wholly owned subsidiary of the Sigma-Tau Group, and is dedicated solely to the global development and commercialization of medicines for patients with rare diseases.  Sigma-Tau Pharmaceuticals, Inc. is based in Gaithersburg, Md.  Since 1989, the company's products have been focused on rare diseases, including kidney disease, certain genetic disorders and cancers.  With more than 7,000 identified rare diseases that affect approximately 25 million patients in the United States, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few.  The company has a substantial development program focused on transplant, cancer, inherited genetic disorders, malaria and other areas of unmet medical need.  For more information about the company, visit www.sigmatau.com.


'/>"/>
SOURCE Sigma-Tau Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
2. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):